Enhance patient care with an all-in-one closed IV catheter System
The BD Nexiva™ closed IV catheter system is the integrated IV catheter demonstrating longer dwell times and reduced complication rates versus the traditional open system.1,2*
BD Nexiva™ IV catheter integrates key features that help provide better care and experience for your patients, efficiently and cost effectively.1
Overall clinician satisfaction has been shown to be significantly higher with Nexiva™ Closed IV Catheter System compared to a non-integrated, open PIVC.⁸
The integrated system is designed with clinician safety in mind:
Watch this video to see the differences in design between the integrated Nexiva™ Closed IV Catheter System and a non-integrated PIVC without blood control technology, which can risk missed insertion, blood leakage, or touch contamination
IV complications may compromise patient care and increase cost, including interrupting drug administration, delaying procedures, and removing and reinserting a new catheter, increasing the risk of catheter failure with each subsequent insertion.11–13
Nexiva™ Catheter System has been clinically demonstrated to significantly reduce IV complications in a number of studies:1,9
In a 2014 clinical study, the longer dwell time§ of Nexiva™ Closed IV Catheter System led to a cost reduction of approximately $1 million per year per 1,000 beds compared with an open system.1
Longer median dwell time compared to an open system1,11
6 Days
Nexiva™ Closed IV Catheters
4 Days
Open-System Catheter
Nexiva™ Catheter System eliminates the need to purchase many separate components. Every Nexiva™ Catheter System contains a pre-attached extension tube and built-in stabilisation platform. Nexiva™ Catheter System is offered in configurations containing BD® MaxZero™ Needle-free Connectors and BD® Q-Syte™ Needle-free Connectors.
IV catheter failure rates lie between 35% and 50%. Compounding this issue, subsequent PIVCs inserted after treatment failure are more likely to fail again, potentially perpetuating the challenges and dissatisfaction for the patient.13
Higher first attempt IV catheter insertion success may be a relief to patients. Studies have shown:
91%
First-attempt insertion success with Nexiva™ Closed IV Catheter System9
35%
Up to 35% of patients receiving an IV require multiple attempts2
Nexiva™ Closed IV Catheter System is offered in four configurations. The dual port configurations allow for the simultaneous administration of two compatible solutions as close to the patient as possible. The single port configurations allow for the administration of one solution, as is common with most PIVCs.
Nexiva™ Closed IV Catheter System is offered in configurations containing MaxZero™ Needle-free Connectors and Q-Syte™ Needlefree Connectors. MaxZero™ Needle-free Connectors are premium needle-free connectors and are offered on both dual port and single port configurations. Q-Syte™ Needle-free Connectors are also offered on dual port configuration.
Together, we all play a part in preventing vascular access complications
Our powerful evidence-based assessments, with analytics and benchmarks, are the first phase of BD Vascular Access Management—and the first step on the path to enhance patient safety, workflow efficiency and cost-effectiveness across the entire patient journey.
Please consult BD product labels and inserts relevant to your geography for any indications, contraindications, hazards, warnings, cautions and instructions for use. Any discussion and/or content regarding BD products is limited to this information and instructions for use.
Please note, not all products, services or features of products and services may be available in your local area. Please check with your local BD representative.
† BD Nexiva Closed IV Catheter System with 3M™ Tegaderm IV Securement Dressing compared to B. Braun Introcan Safety® Catheter with Statlock® IV Ultra Stabilization Device and non-bordered dressing.
‡ with a PTFE catheter
§ compared to an open system
* converted from US Dollar to Euro on May 23, 2025
Nexiva™ Catheter System has been shown to deliver higher clinician satisfaction, improved clinician safety and a reduction in overall complication rates versus non-integrated, open systems.
Nexiva™ Catheter System is backed by evidence in peer-reviewed journals from as early as 20091 to as recently as 2024.2
Nexiva™ Diffusics™ Closed IV Catheter System is also backed by peer-reviewed journals and infusion guidelines. Infusion Therapy Standards of Practice state to consider a fenestrated catheter for a contrast-based radiographic study and in coronary CTA.3
Nexiva™ Diffusics™ Catheter System is the only peripheral IV catheter with a diffusion catheter tip specifically designed for power injection.
Closed IV Catheter
| Comparative
| Data gathered | Year
| Study type | Journal | Authors |
| Nexiva™ | Various | Catheter failure, dislodgement, occlusion, phlebitis | 2024 | Systematic review/ meta analysis2 | Journal of Vascular Access | Gidaro A, Quici M, Giustivi D, et al. |
| Nexiva™ | BD® Insyte™ Autoguard™ | Complications, dislodgement, dwell time, infiltration, occlusion, phlebitis | 2023 | Randomised controlled trial4 | European Journal of Oncology Nursing | Gerceker GO,
Yildirim BG, Onal A, et al. |
| Nexiva™ | B. Braun
Insyte™ | Catheter-associated bloodstream infection, clinician satisfaction, cost savings/utilisation reduction, dislodgement/ leaking, dwell time, infiltration/extravasation, local infection, insertion success, occlusion, phlebitis | 2022 | Randomised controlled trial5 | Journal of Hospital Medicine | Rickard CM,
Larsen E, Walker RM, et al. |
| Nexiva™ | Smiths Jelco ProtectIV® Plus | Clinician satisfaction, dwell time, infection, infiltration, pain, phlebitis | 2019 | Prospective, quasi-experimental6 | Journal of Infusion Nursing | Penoyer D, Fowler S, Bennett M |
| Nexiva™ | None | Blood exposure, dislodgement, kinking, leaking, phlebitis, restarts | 2017 | Observational7 | Journal of Vascular Access | deRosenroll A |
| Nexiva™ | Medikit | Bending and kinking, blood exposure, cost savings/utilisation reduction,dislodgement, dwell time, extravasation, insertion success, obstruction, phlebitis | 2014 | Quasi- randomized study8 | Journal of Vascular Access | Tamura N, Abe S, Hagimoto K, et al. |
| Nexiva™ | B. Braun Vasocan® Safety | Catheter-related infection, cost savings/utilisation reduction, dwell time, infiltration/extravasation, insertion success, occlusion, pain, painful hematoma, phlebitis | 2014 | RCT9 | Journal of Hospital Infection | González López J, Arribi Vilela A, Fernández Del, Palacio E, et al. |
| Nexiva™ | B. Braun Introcan Safety® (non- winged) with BD® StatLock™ | Clinician satisfaction, cost savings/utilisation reduction, dislodgement, dwell time, infiltration, insertion success, leaking, phlebitis | 2010 | RCT10 | Journal of Infusion Nursing | Bausone-Gazda D, Lefaiver CA, Walters SA, et al. |
| Nexiva™ | None | Clinician satisfaction, clotting, dislodgement, infiltration, leaking, restarts, securement | 2009 | Pre-and post-use survey1 | Journal of the Association of Vascular Access | McNeil E, Hines N, Phariss R |
Catalog no. | Colour | Gauge | Catheter
| Gravity flow rate
| Maximum power
|
| 383571 | Yellow | 24 | 19 | 18 | Not for use with power injectors |
| 383572 | Blue | 22 | 25 | 33 | 3.0 |
| 383573 | Blue | 22 | 45 | 30 | 3.0 |
| 383576 | Pink | 20 | 25 | 61 | 4.0—5.5 |
| 383577 | Pink | 20 | 32 | 58 | 4.0—5.5 |
| 383578 | Pink | 20 | 45 | 51 | 4.0—5.5 |
| 383579 | Green | 18 | 32 | 84 | 4.0—7.0 |
| 383580 | Green | 18 | 45 | 79 | 4.0—7.0 |
*22-18 G. Nexiva™ Catheter System - Dual Port with MaxZero™ Needle-free Connectors attached are suitable for use with power injection. The catheter system has been tested at flow rates; however, due to variations in add-on devices, tubing, contrast media temperature and pressure limit settings these flow rates may not be achievable.
Catalog no. | Colour | Gauge | Catheter
| Gravity
| Max power
|
| 383551 | Yellow | 24 | 19 | 18 | Not for use with power injectors |
| 383552 | Blue | 22 | 25 | 33 | 3.0 |
| 383553 | Blue | 22 | 45 | 30 | 3.0 |
| 383556 | Pink | 20 | 25 | 61 | 4.0—5.5 |
| 383557 | Pink | 20 | 32 | 58 | 4.0—5.5 |
| 383558 | Pink | 20 | 45 | 51 | 4.0—5.5 |
| 383559 | Green | 18 | 32 | 84 | 4.0—7.0 |
| 393560 | Green | 18 | 45 | 79 | 4.0—7.0 |
*22–18 G BD Nexiva™ Catheter System — Single Port with MaxZero™ Needle-free Connectors attached are suitable for use with power injection. The catheter system has been tested at flow rates; however, due to variations in add-on devices, tubing, contrast media temperature and pressure limit settings these flow rates may not be achievable.
Catalog no. | Colour | Gauge | Catheter
| Gravity flow rate
| Maximum power
|
| 383531 | Yellow | 24 | 19 | 18 | Not for use with power injectors |
| 383532 | Blue | 22 | 25 | 33 | 3.0 |
| 383536 | Pink | 20 | 25 | 61 | 4.0—5.5 |
| 383537 | Pink | 20 | 32 | 58 | 4.0—5.5 |
| 383538 | Pink | 20 | 45 | 51 | 4.0—5.5 |
| 383539 | Green | 18 | 32 | 84 | 4.0—7.0 |
| 383540 | Green | 18 | 45 | 79 | 4.0—7.0 |
*Q-Syte™ Needle-free Connectors must be removed prior to power injection. The catheter system has been tested at flow rates; however, due to variations in add-on devices, tubing, contrast media temperature and pressure limit settings these flow rates may not be achievable.
Catalog no. | Colour | Gauge | Catheter
| Gravity flow rate
| Maximum power
|
| 383511 | Yellow | 24 | 19 | 18 | Not for use with power injectors |
| 383512 | Blue | 22 | 25 | 33 | 3.0 |
| 383513 | Blue | 22 | 45 | 30 | 3.0 |
| 383516 | Pink | 20 | 25 | 61 | 4.0—5.5 |
| 383517 | Pink | 20 | 32 | 58 | 4.0—5.5 |
| 383518 | Pink | 20 | 45 | 51 | 4.0—5.5 |
| 383519 | Green | 18 | 32 | 84 | 4.0—7.0 |
| 383520 | Green | 18 | 45 | 79 | 4.0—7.0 |
*The catheter system has been tested at flow rates; however, due to variations in add-on devices, tubing, contrast media temperature and pressure limit settings these flow rates may not be achievable.
BD's collection of literature on industry and on our offerings gives you information you can use to continue striving for excellence.
BD offers training resources to help improve your clinical practices as part of our goal of advancing the world of health.
